NXERA PHARMA CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,489 JPY | -1.46% |
|
-0.80% | +4.71% |
| Sales 2024 * | 35.22B 228M | Sales 2025 * | 38.94B 252M | Capitalization | 135B 874M |
|---|---|---|---|---|---|
| Net income 2024 * | 951M 6.15M | Net income 2025 * | 3.47B 22.45M | EV / Sales 2024 * | 3.53 x |
| Net cash position 2024 * | 10.81B 69.95M | Net cash position 2025 * | 12.21B 78.97M | EV / Sales 2025 * | 3.16 x |
| P/E ratio 2024 * |
67.4
x | P/E ratio 2025 * |
26.6
x | Employees | 350 |
| Yield 2024 * |
-
| Yield 2025 * |
0.05% | Free-Float | 88.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nxera Pharma Co., Ltd.
More recommendations
More press releases
| 1 day | +3.28% | ||
| 1 week | -5.03% | ||
| Current month | -9.09% | ||
| 1 month | +0.13% | ||
| 3 months | +6.26% | ||
| 6 months | +7.77% | ||
| Current year | +6.33% |
1 week
1 451.00
1 552.00
1 month
1 451.001 670.00
Current year
1 296.001 826.00
1 year
1 296.003 185.00
3 years
991.003 185.00
5 years
991.003 185.00
10 years
463.506 545.00
| Managers | Title | Age | Since |
|---|---|---|---|
Chris Cargill
CEO | Chief Executive Officer | 40 | 17-09-19 |
Shinichi Tamura
FOU | Founder | 74 | 90-06-21 |
| Director of Finance/CFO | - | 22-03-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shinichi Tamura
FOU | Founder | 74 | 90-06-21 |
Noriaki Nagai
BRD | Director/Board Member | 66 | 19-03-26 |
Rolf Soderstrom
BRD | Director/Board Member | 58 | 20-03-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.92% | 24 M€ | -10.38% | ||
| 1.17% | 16 M€ | -8.26% | ||
| 0.55% | 15 M€ | +4.35% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 1,489 | -1.46% | 197 100 |
| 24-04-18 | 1,511 | +3.28% | 762,900 |
| 24-04-17 | 1,463 | +0.48% | 1,376,800 |
| 24-04-16 | 1,456 | -3.77% | 891,700 |
| 24-04-15 | 1,513 | +0.87% | 950,200 |
Delayed Quote Japan Exchange, April 18, 2024 at 02:00 am EDT
More quotes
Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1,511
JPY
Average target price
2,100
JPY
Spread / Average Target
+38.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.33% | 846M | |
| -5.32% | 84.57B | |
| +3.95% | 39.93B | |
| -26.37% | 27.93B | |
| +52.09% | 24.21B | |
| -6.59% | 17.17B | |
| -32.37% | 13.93B | |
| -10.45% | 12.3B | |
| -15.88% | 11.84B | |
| -2.85% | 7.91B |
- Stock Market
- Equities
- 4565 Stock
